Commonly used tumor markers such as beta-hCG and AFP, along with the initial International Federation of Gynecology and Obstetrics (FIGO) stage, can help assess treatment response, guide follow-up, and predict overall survival (OS) [6]. Here, AFP is linked to neoplasm.